[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LifeBridge Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,81,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100577106","phase-4-platelet-rich-plasma-versus-corticosteroids-in-hip-osteoarthritis-pain-100577106",false,"NCT06793982","Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain","The Efficacy of Platelet Rich Plasma Compared With Corticosteroid Injections for the Treatment of Pain Associated With Hip Osteoarthritis","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 21-80 years\n* Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis\n* Indicated for a Hip injection to treat Hip OA symptoms\n\nExclusion Criteria:\n\n* Any injections into the target Hip within three months\n* Current overlying skin infection\n* Current or previous diagnosis of \"chronic pain\"\n* Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)\n* Allergy to any potential ingredients or medications utilized in any of the two groups\n* Treatment with another investigational drug or other intervention for pain\n* Diagnosis of Diabetes Mellitus\n* If female, pregnant or planning to be pregnant within the following 3 months or study duration\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation","ALL","21 Years","80 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.",[27],"Hip Osteoarthritis",[29,30,31,32,33],"platelet rich plasma","hip osteoarthritis","PRP","hip OA","Corticosteroids","RECRUITING","2025-03-11",{"date":37,"type":38},"2025-03-14","ACTUAL",{"date":40,"type":38},"2024-02-21",{"date":42,"type":21},"2025-12-01",{"name":44,"class":45},"LifeBridge Health","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":70,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100424990","prospective-functional-gait-and-outcome-comparison-study-of-medial-pivot-versus-single-radius-design-for-total-knee-arthroplasty-100424990","NCT04814082","Prospective Functional, Gait, and Outcome Comparison Study of Medial Pivot Versus Single Radius Design for Total Knee Arthroplasty","Prospective Functional, Gait, and Outcome Comparison Study of Medial Pivot","Inclusion Criteria:\n\n* Subject is male or non-pregnant female aged between 18 and 75 years of age.\n* Subject is willing to provide informed consent to participate in the research study.\n* Subject is indicated for a primary total knee arthroplasty (TKA) based on the approved labeling of knee implant, either a medial pivot or single radius design, specifically: MicroPort Evolution Medial-Pivot Knee System, Cruciate Retaining (CS) or Stryker Triathlon Tritanium (CS)\n* Subject does not have a history of previous prosthetic replacement device on the operative knee.\n* Subject is currently ambulating and does not have a condition on the contralateral limb in the opinion of the investigator that would interfere with the gait laboratory evaluations.\n* Subject is willing and able to comply with the schedule of events for the study and is available to return to the clinic for all required follow-up visits.\n\nExclusion Criteria:\n\n* Subject has a Body Mass Index (BMI) \\>40\n* Subject has a diagnosis of avascular necrosis or inflammatory arthritis.\n* Subject has any mental or neuromuscular disorder that would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care.\n* Subject is a prisoner\n* Subject has any condition, in the opinion of the Investigator that might interfere with the evaluation of the study objectives.","18 Years","75 Years",{"count":57,"type":21},100,[59],"NA","Patients with degenerative joint disease can effectively be treated with a primary total knee replacement to reduce pain and improve function in their daily lives. Theoretically, achievement of normal knee motion using a medial pivot design in total knee replacements can be recreated in comparison to single radius designs, which could lead to an improvement in post-surgical outcomes and satisfaction with the procedure. The aim of this study is to compare two types of implant designs (medial pivot and single radius) in a total knee replacement using clinical outcomes, patient reported outcomes, and overall function assessed by a specialized gait laboratory.",[62,63,64,65,66,67,68,69],"Osteoarthritis, Knee","Knee Osteoarthritis","Osteoarthritis Knees Both","Osteoarthritis Knee Left","Osteoarthritis Knee Right","Knee Pain Chronic","Knee Disease","Arthropathy of Knee Joint",[71,72],"Total Knee Arthroplasty","Total Knee Replacement","2025-01-20",{"date":75,"type":38},"2025-01-22",{"date":77,"type":38},"2021-02-01",{"date":79,"type":21},"2030-07-01",{"name":44,"class":45},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":46},"100418513","phase-4-the-pericapsular-nerve-block-in-total-hip-arthroplasty-100418513","NCT04729686","The Pericapsular Nerve Block in Total Hip Arthroplasty","The Pericapsular Nerve Block in Total Hip Arthroplasty: A Randomized, Controlled Trial","PENG","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach\n* ASA score of 1 to 3\n* Indicated for one of the two nerve block groups\n* Must be opioid naïve at screening as defined by the FDA - According to the Food and Drug Administration, opioid-tolerant patients were those currently receiving or who had previously received 60 mg PO morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg PO oxycodone per day, 8 mg PO hydromorphone per day, 25 mg PO oxymorphone per day, 60 mg PO hydrocodone per day, or an equivalent dose of another opioid for a duration of one week or longer (16)\n\nExclusion Criteria:\n\n* Current or previous diagnosis of \"chronic pain\"\n* Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)\n* Diagnosis of ankylosing spondylitis\n* Allergy to any potential medications utilized in any of the two groups\n* Conversion of patient to general anesthesia intraoperatively\n* Treatment with another investigational drug or other intervention for pain\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation",{"count":90,"type":21},78,[24],"In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.",[27,94],"Hip Arthropathy",[96,97,98,99,100],"Total Hip Arthroplasty","Total Hip Replacement","Hip Arthroplasty","Hip Replacement","Postoperative Pain",{"date":75,"type":38},{"date":103,"type":38},"2020-12-09",{"date":42,"type":21},{"name":44,"class":45},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":16,"minAge":54,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100568037","in-vitro-demonstration-of-direct-platelet-related-effects-of-pcsk9-enzyme-100568037","NCT06675994","In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme","Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways: In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme","Inclusion Criteria:\n\n* Healthy subjects (n=40): 18-50 years old male and female subjects without any conditions or taking any agents or food supplements that may influence platelet function as determined by the study principal investigator.\n* Subjects with CV risk factors (n=40): 18-50 years old male and female subjects with at least three of the following CV risk factors:\n\nHistory of hypercholesterolemia, hypertension, overweight, current smoker, prediabetes or diabetes who are only on metformin and insulin, and family history of coronary artery, peripheral artery, or cerebrovascular disease.\n\nOverweight is defined as subjects with BMI ≥25 kg\u002Fm2 (https:\u002F\u002Fwww.heart.org\u002Fen\u002Fhealthy-living\u002Fhealthy-eating\u002Flosing-weight\u002Fbmi-in-adults).\n\nDiabetes is defined as haemoglobin (Hb)A1c ≥6.5%, prediabetes =5.7%-6.4%) (https:\u002F\u002Fdiabetes.org\u002Fabout-diabetes\u002Fdiagnosis)\n\nExclusion Criteria:\n\n* Subjects with Diabetes mellitus, who are on GLP-1 agonists or SGLT2 inhibitors.\n* Subjects on high dose statin therapy or PCSK9 therapy.\n* Prior coronary of cerebrovascular event requiring intervention.\n* Use of any antiplatelet or anticoagulant therapy within 14 days of enrollment.\n* Subjects with a history of chronic kidney disease, liver disease, pancreatitis, HIV, hepatitis, and active cancer, active infection, or any other medical condition or concomitant medications as determined by the investigator that may affect study results.\n* Pregnant",true,"50 Years",{"count":116,"type":21},80,"OBSERVATIONAL","Proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and therapeutic target for hypercholesterolemia and atherosclerotic cardiovascular disease (CVD). Furthermore, research from in-vitro and in-vivo animal models suggest that the inhibition of PCSK9 expression may suppress platelet activation, and systemic inflammation thereby reducing thrombotic risk. Taken together, these data support the lower rates of myocardial infarction, stroke, and coronary revascularization in subjects with increased CVD risk in clinical trials with alirocumab (Praluent) and evolocumab (Repatha) as compared to placebo. The main aim of this single center, exploratory in-vitro evaluation is to investigate the direct role of PCSK9 on platelet activation and aggregation using blood collected from a diverse population of antiplatelet naïve healthy volunteers (n=40) and subjects with CVD risk factors (n=40) between the 18-50 years of age. All procedures including consenting, collection of clinical data, and lab processing will occur at the Sinai Center for Thrombosis Research. The results of this study will provide a better understanding of cardioprotective effects of PCSK9 inhibition beyond lipid lowering.",[120,121,122,123,124,125,126,127,128],"Healthy","Hypercholesterolemia","Hypertension","Overweight","Prediabetes","Diabetes","Family History of Coronary Artery Disease","Family History of Peripheral Artery Disease","Family History of Cerebrovascular Disease","NOT_YET_RECRUITING","2024-11-04",{"date":132,"type":38},"2024-11-06",{"date":134,"type":21},"2024-12-01",{"date":136,"type":21},"2025-12-30",{"name":44,"class":45},""]